Jones Financial Companies
RNAC icon

Jones Financial Companies’s Cartesian Therapeutics RNAC Stock Holding History

Jones Financial Companies’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$1.44K – 4890
2025
Q4 		$1.44K Buy
+200
New +$1.62K ﹤0.01% 3925

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jones Financial Companies's RNAC Position: Q1 2026 in Review

Jones Financial Companies sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 200 shares — an estimated $1.44K sold.

Jones Financial Companies first reported a position in RNAC in Q4 2025 and held it in 1 quarter. The position peaked at $1.44K in Q4 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Jones Financial Companies reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jones Financial Companies sold 200 Cartesian Therapeutics shares in Q1 2026, an estimated $1.44K.
  • Jones Financial Companies first reported a position in Cartesian Therapeutics in Q4 2025 and held it in 1 quarter.
  • Jones Financial Companies's Cartesian Therapeutics position peaked at $1.44K in Q4 2025.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.